RANI SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWRani Therapeutics Reports Q3 2026 Financial Results and Provides Corporate Update

Nov 9, 2026

8-K

Rani Therapeutics Reports Q2 2026 Financial Results and Corporate Updates

Aug 13, 2026

8-K

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

Aug 4, 2026

8-K

Rani Therapeutics Appoints Nicholas M. Maestas as Chief Financial Officer

Jun 29, 2026

8-K

Rani Therapeutics Holdings, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 28, 2026

8-K

Rani Therapeutics Announces $20 Million Registered Direct Offering

May 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

May 26, 2026

424B5

SHELF OFFERING | Shares amount: 42,633,337 | Warrants amount: 125,000,004

Dec 3, 2025

424B5

REGISTERED OFFERING

Jul 16, 2025

424B5

SHELF OFFERING | Shares amount: 13,160,172 | Warrants amount: 13,160,172 .65

Jul 11, 2025

424B5

May 2025 ATM | Amount sold to date: $0 | Float: 32,706,577

May 16, 2025

424B5

Oct 16, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 15, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 26, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Nov 7, 2025

S-3

SHARE RESALE REGISTRATION

Nov 7, 2025

S-3

August 2025 SHELF | Float: 47,094,467 | Amount sold to date: $3,000,000

Aug 8, 2025

S-3

SHARE RESALE REGISTRATION

Jul 3, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 16, 2026

DEF 14C

Form DEF 14C - Other definitive information statements

Dec 5, 2025

PRE 14C

Form PRE 14C - Other preliminary information statements

Nov 25, 2025

DEF 14C

Form DEF 14C - Other definitive information statements

Jul 10, 2025

PRE 14C

Form PRE 14C - Other preliminary information statements

Jun 30, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Imran Talat (Reporting)

Sep 29, 2026

Javadi Alireza (Reporting)

Sep 29, 2026

SCHEDULE 13G/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 14, 2026

Gilson Michelle (Reporting)

Aug 4, 2026

Gilson Michelle (Reporting)

Aug 4, 2026

SCHEDULE 13G/A

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Jul 31, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 4, 2025

CORRESP

Form CORRESP - Correspondence

Dec 1, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 15, 2025

CORRESP

Form CORRESP - Correspondence

Aug 12, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 12, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 14, 2025

Rani Therapeutics Holdings, Inc. RANI · SEC Filings